Minimizing blood loss in burn surgery

Safe and successful restriction of transfusion in burn patients

An acceptable strategy for transfusion of burn patients has not been specifically identified. In 1999, we empirically adopted a hemoglobin (Hb) transfusion trigger of 7.0 g/dl or greater in our burn center. The purpose of this study was to evaluate the effects of this restrictive transfusion strategy. Retrospective comparison of adults with 20% or greater TBSA treated from 1999 to 2004 (restrictive group; REST) with patients treated before our adoption of the restrictive transfusion strategy (1997-1998: liberal group; LIB). The REST group (n = 135, age 42 +/- 17 years, %TBSA burn 37 +/- 14, and 26% incidence of inhalation injury) did not differ significantly from the LIB group (n = 37, age 42 +/- 16 years, %TBSA burn 38 +/- 17, and 35% inhalation injury). The Hb triggering a transfusion was 7.1 +/- 1.2 g/dl in the REST group, compared with 9.2 +/- 2.1 g/dl in the LIB group (P < .001). The REST group received significantly fewer units of blood per day than the LIB Group. Patients in the REST group appeared to have significantly better organ function, and there were no differences between the groups in the incidence of acute myocardial infarction. Mortality at 30 days was significantly lower in the REST group (19% vs 38%; P = .03), as was overall in-hospital mortality (22% vs 46%; P = .003). Transfusion restriction appears to be safe and resulted in fewer transfusions among this group of burn patients. Prospective studies are needed before broadly recommending a transfusion trigger of 7.0 g/dl.

Rescue treatment with recombinant factor VIIa is effective in patients with life-threatening bleedings secondary to major wound excision: a report of four cases

Major burn wound excision is associated with excessive perioperative blood loss. Treatment of massive microvascular bleeding represents a special problem in the burn setting, characterized by extensive damage at the capillary level, and resulting in a profound blood loss; which together with the consumptive states makes adequate replacement therapy with coagulation factors and platelets difficult. We described our experience with rescue treatment with rFVIIa in four patients undergoing major wound excision, developing life-threatening perioperative bleeding, and not responding to conventional therapy. Hemostasis was achieved within 15 minutes of intravenous rFVIIa administration, at a dose of 100 microg/kg, in all patients. No treatment-related adverse events, in particular, no thromboembolic events were observed. We conclude that rFVIIa may be an effective hemostatic treatment for patients undergoing major wound excision developing life-threatening bleedings.

A defined period of sensitivity of an experimental burn wound to a second injury

We sought to determine whether the zone of stasis of an experimental burn exhibits a defined period of sensitivity to a sublethal exposure to ischemia. A standard burn injury was inflicted on the abdominal skin of rats consisting of two burn areas separated by a 5-mm strip corresponding to the zone of stasis. Either immediately or after a delay of 24, 48, or 72 hours, the area of the burn and interspace was elevated as a flap based on the inferior epigastric vessels and subjected to a 5-hour period of ischemia that in itself is insufficient to cause necrosis. Forty-eight hours later, the flap was harvested to assess the viability of the panniculus carnosus. Necrosis of the panniculus in the interspace was not seen in any animal where burn was not subjected to ischemia (n = 6) or in any flap subjected to a 5-hour period of ischemia immediately (less than 30 minutes) after the burn (n = 7). In contrast, when the period of ischemia was delayed 24 hours after the burn, necrosis of the muscle in the interspace was seen in 5 out of 6 flaps (P = .0047), as it was in rats in which the start of ischemia was delayed 48 hours (n = 2). However, this effect was abolished with a delay of 72 hours (n = 2). These findings show that the zone of stasis displays increased sensitivity to ischemia 24 to 48 hours after burning. Thus, sequential subnecrotic injuries can have a cumulative effect, but a delay between the two is required.

DEVELOPMENT OF PATIENT PATHWAYS FOR THE SURGICAL MANAGEMENT OF BURN INJURY

BACKGROUND

There are many reasons for the development of patient pathways in burn surgery introduced at the Royal Adelaide Hospital in South Australia at the beginning of January 2005. These include education, standardization of technique, scheduling of surgical episodes and rationalization of the use of expensive therapies.

METHODS

A critical appraisal of both evidence based on published work and personal/peer experience has been used to generate the current pathways.

RESULTS

The year 2005 was the busiest in the history of the hospital, both in numerical terms and in the proportion of major burn injuries. These protocols were effective in enabling us to cope with negligible mortality.

CONCLUSION

Although the first draft pathways work in our unit, they will undergo regular audit. It is hoped that they will form a template that can assist other services to create their own pathways.

The burned hand: optimizing long-term outcomes with a standardized approach to acute and subacute care

Deep partial- and full-thickness burns to the hands are common and the source of significant potential morbidity for the patient. This article emphasizes that when these burns are managed by an experienced team of burn surgeons, rehabilitation therapists, and nurses, using a standardized protocol, good long-term functional outcomes may be reliably obtained in most cases. The details of the author's standardized protocol, as well as late outcomes achieved using this approach, are discussed.

Transfusion-free pediatric burn surgery: techniques and strategies

More than 1.3 million children sustain burns each year, resulting in 40,000 admissions and more than 3000 pediatric deaths. Pediatric burn surgery has been described as excessively bloody. Strategies to reduce intraoperative blood loss include the use of topical thrombin and epinephrine, extremity tourniquets, acute normovolemic hemodilution, and hypotensive anesthesia. This study reviews the single surgeon pediatric burn experience at a children's hospital and describes a comprehensive blood conservation protocol to achieve transfusion-free pediatric burn surgery. A retrospective chart review of consecutive pediatric burn surgeries from July 2000 to April 2002 was performed. Patient demographics, burn characteristics, treatment, blood loss, laboratory values, transfusion history, and complications were reviewed. Blood loss per percent total body surface area (TBSA) treated as well as percent total blood volume (TBV) loss divided by percent TBSA treated were calculated. A total 31 burn surgeries in 23 patients were reviewed. The average age was 7 years (range, 9 months-17 years). There were 17 extremity, 6 trunk, and 2 head/neck burns. The average TBSA burned was 15% (range, 1-55%). The protocol to reduce intraoperative blood loss consisted of the debridement of full-thickness burns with electrocautery and partial-thickness burns with dermabrasion. All debrided or harvested surgical sites were treated immediately with epinephrine solution-soaked pads. All graft harvest sites were injected with an epinephrine solution before harvesting split-thickness skin grafts. The average TBSA treated per surgery was 7% (range, 1-29%). The average blood loss per percent TBSA treated was 15 mL (range, 0.7-37 mL). The average percent TBV/percent TBSA was 0.76% (range, 0.04-3.6%). All 20 patients underwent surgical debridement, 7 patients were treated with AlloDerm and ultrathin split-thickness skin grafts, 2 with full-thickness skin grafts, and 17 with split-thickness skin grafts alone. Five children required blood transfusions. These burns averaged 32% TBSA (range, 20-55%). All 5 children receiving transfusions had anemia of thermal injury and demonstrated an average preoperative drop in hematocrit of 12% (range, 10-14%). There was a 29% complication rate, with 7 patients experiencing partial graft loss, and 1 patient who developed a postgraft contracture that required revisional surgery. There was a single mortality secondary to systemic inflammatory response syndrome and acute respiratory distress syndrome. After the proposed pediatric burn treatment protocol, intraoperative blood loss requiring transfusion can be minimized or eliminated. Large TBSA burns must be surveilled for burn wound anemia that may ultimately require blood transfusion.

State of the Art in Burn Treatment

Optimal treatment of burn victims requires deep understanding of the profound pathophysiological changes occurring locally and systemically after injury. Accurate estimation of burn size and depth, as well as early resuscitation, is essential. Good burn care includes also cleansing, debridement, and prevention of sepsis. Wound healing, is of major importance to the survival and clinical outcome of burn patients. An ideal therapy would not only promote rapid healing but would also act as an antiscarring therapy. The present article is a literature review of the most up-to-date modalities applied to burn treatment without overlooking the numerous controversies that still persist.

A prospective double blind randomized study comparing the need for blood transfusion with terlipressin or a placebo during early excision and grafting of burns

INTRODUCTION

Early excision and skin grafting has become the standard of good burn management, but it is associated with major blood loss.

AIM

To determine the haemostatic effect of terlipressin compared with placebo.

MATERIAL AND METHODS

Fifty-one patients with burns of 10-20% total body surface area had early excision and split skin grafting of deep burns. The surface area of the burn wound and of the healed graft were measured by planimetry. The patients were randomly allocated to medication, either terlipressin or placebo. Blood loss and number of transfused units of blood were recorded.

RESULTS

Twenty-one patients received terlipressin, 13 received terlipressin late (cross-over) and 17 received placebo. Six out of 21 patients exposed to terlipressin were transfused with eleven units of packed red blood cells. Seven out of 13 patients crossed over from placebo to terlipressin (late terlipressin) were transfused with 17 units of blood. Eight out of 17 patients exposed to the placebo were transfused with 22 units of blood (P < 0.05). Graft healing was 1055 +/- 609 cm2 out of 1452 +/- 11 cm2 in terlipressin and 914 +/- 633 cm2 out of 1288 +/- 720 cm2 in the placebo group (n.s.).

CONCLUSION

Terlipressin reduced the need for blood transfusion by a factor of 2.5 compared to a placebo without impairment of graft healing.

What Are the Acute Cardiovascular Effects of Subcutaneous and Topical Epinephrine for Hemostasis During Burn Surgery?

Although subcutaneous and topical epinephrine are widely used for hemostasis during burn surgery, the acute systemic cardiovascular effects of the epinephrine are neither well documented nor completely understood. The purpose of this work was to prospectively study the acute cardiovascular responses to epinephrine (epi) administered subcutaneously and topically during burn surgery. Consecutive patients who received subcutaneous and topical epi during burn surgery were monitored prior to the administration of epi, at 2-minute intervals during subcutaneous epi infiltration, and then after epi infiltration (during which time, topical epi was applied). This period of monitoring lasted up to 20 minutes and was referred to as an epinephrine event (EE). A total of 100 EEs from 38 operations in 24 patients (mean +/- SD: age 43 +/- 16 years, mean % TBSA burn 23 +/- 17%) were studied. The mean dose of subcutaneous epi was 30 +/- 30 microg/kg. Although all patients received topical epi, it was impossible to document the topical dose. There was no significant increase in heart rate from baseline, and no arrhythmias occurred. Mean arterial pressure (MAP) did acutely increase significantly by 17.0 +/- 14.1% from baseline (P =.009) and increased more than 10% from baseline in 64/100 EEs. However, the increase in MAP was independent of the dose of epi (r =.053). The increase in MAP was not clinically significant, did not require intervention, and did not appear to be related to the type of wound that received epi (donor site vs burn wound), or the depth of anesthesia, analgesia, or sedation. On the basis of these findings, the use of subcutaneous and topical epi appears to be safe and produces minimal acute cardiovascular effects.